A B S T R A C T The catabolic pathways of streptokinase, plasmin, and activator complex prepared with human plasminogen were studied in mice. '25I-streptokinase clearance occurred in the liver and was 50% complete in 15 min. Incubation with mouse plasma had no effect on the streptokinase clearance rate. Complexes of plasmin and a2-plasmin inhibitor were eliminated from the plasma by a specific and saturable pathway. Competition experiments demonstrated that this pathway is responsible for the clearance of injected plasmin. Streptokinase-plasminogen activator complex formed with either 1251-plasminogen or 125I-streptokinase cleared in the liver at a significantly faster rate than either of the uncomplexed proteins (50% clearance in <3 min). Streptokinase incubated with human plasma also demonstrated this accelerated clearance. p-Nitrophenyl-p '-guanidinobenzoate-HCl or pancreatic trypsin inhibitor-treated complex cleared slowly compared with untreated complex independent of which protein was radiolabeled. Significant competition for clearance was demonstrated between a2-macroglobulin-trypsin and activator complex only when the plasmin(ogen) was the radiolabeled moiety. Large molar excesses of a2-plasmin inhibitor-plasmin failed to retard the clearance of activator complex. Hepatic binding of streptokinase-plasmin, in liver perfusion experiments, was dependent upon prior incubation with plasma (8-10% uptake compared to a background of -2.5%). Substitution of human ca2-mac-
INTRODUCTION
Streptokinase is a bacterial protein that possesses no inherent enzymatic activity, but forms a noncovalent one-to-one stoichiometric complex with human plasminogen or plasmin (1, 2) . This complex functions as a plasminogen activator. The association reaction is extremely rapid and the two proteins do not readily dissociate under neutral, nondenaturing conditions (3, 4) .
The therapeutic potential of streptokinase as a thrombolytic agent was first demonstrated with extravascular clots by Tillett and Sherry (5) . In a subsequent study streptokinase was found to be equally effective in the lysis of intravascular clots (6) . Patients diagnosed in the early stages of myocardial infarction were considered as candidates for streptokinase therapy by Fletcher et al. (7) . Since then, numerous studies have been published concerning streptokinase therapy in deep vein thrombosis and myocardial infarction.
Little is known about the metabolism of streptokinase. Plasma elimination studies conducted in dogs and organ distribution studies in mice have yielded some-what inconsistent results (8) (9) (10) . None of these studies have addressed the issue of species variability in the reactivity of plasminogen with streptokinase. Limited association of intravenously administered streptokinase with plasminogen to form activator complex occurs in the circulation of dogs, and none in the circulation of mice (11) . In human patients, however, the major fraction of an injected streptokinase dose would be expected to immediately form activator complex (3, 11) . How the activator complex is eliminated from the circulation is unclear especially in consideration of its large size (>120,000) and numerous studies that detail its lack of reactivity with the major plasma protease inhibitors (3, 12, 13) .
In this investigation, the plasma elimination pathways of streptokinase, plasmin, and activator complex are studied with both in vitro experiments and in vivo experiments in mice. Use of the mouse as a model for the catabolism of these proteins in man offers the following advantages. (a) Mouse plasminogen is completely nonreactive with streptokinase (11) . This finding, which is confirmed here, permits a comparison of the catabolism of free streptokinase to streptokinase activator complex formed in vitro with human plasminogen before injection. (b) Human and mouse protease inhibitors including a2-macroglobulin (a2M), a1-proteinase inhibitor, and antithrombin III have been shown to bind proteases and clear on receptor systems in mouse without distinction attributable to crossing species lines (14) (15) (16) .' Evidence is presented here suggesting that protease inhibitors are critical in the elimination of both free plasmin and streptokinaseplasmin(ogen) complex. a2-Plasmin inhibitor (a2PI)2 is shown to be the major regulatory protein for injected plasmin in the dose range studied. This finding is in good agreement with studies that consider a2PI the primary inhibitor of circulating plasmin (17) (18) (19) . Alternatively, when plasmin is injected as part of a preformed complex with streptokinase, a2M reacts with the protease and functions in the clearance of the complex.
METHODS
Reagents.
P-nitrophenyl-p'-guanidinobenzoate-HCI (PNPGB) was purchased from Sigma Chemical Co., St. Louis, MO. '25Iodine and lactoperoxidase coupled to Sepharose were obtained from New England Nuclear, Boston, MA and P-L Biochemicals, Milwaukee, WI, respectively.
The plasmin substrate H-D-valyl-L-leucyl-L-lysine-p-ni- 1 Gonias, S. L., A. Balber, W. J. Hubbard, and S. V. Pizzo.
Manuscript in preparation. 2 Abbreviations used in this paper: a2M, a2-macroglobulin; a2PI, a2-plasmin inhibitor; PNPGB, p-nitrophenyl-p'-guanidinobenzoate-HCI; PTI, pancreatic trypsin inhibitor.
troanilide. 2HCI (S-2251) is a Kabi Company product. Electrophoresis reagents were purchased from Bio-Rad Laboratories, Richmond, CA. All other reagents were of the best commercial grade available.
Proteins. Plasminogen was purified from human plasma by affinity chromatography on lysine-Sepharose as described by Deutsch and Mertz (20) and modified by Brockway and Castellino (21) to include gradient elution. Urokinase was purchased from Abbot Diagnostics, North Chicago, IL. Highly purified streptokinase was prepared from Kabikinase (Kabi Company) as previously described (22) . Plasminogen was activated by incubation at a 500-fold molar excess with streptokinase for 40 min in sodium phosphate-buffered saline pH 7.4. Activation was also accomplished after incubation of 10 ,sg of plasminogen with 6 Ploug units of urokinase for 2 h at 370C. Plasminogen preparations that were activated by either method were electrophoresed on NaDODSO4 gels after reduction with dithiothreitol. Gels were scanned using a Gelman ACD-15 automatic integrating densitometer (Gelman Sciences, Inc., Ann Arbor, MI). Before reaction with streptokinase or urokinase, plasminogen electrophoresed as a single band (Glu-plasminogen) (23) . Activation was assessed as the decrease in protein electrophoresing as plasminogen accompanied by an increase in protein electrophoresing in new bands attributable to the heavy and light chains of plasmin (23) . Only preparations that were >95% activated, as determined by densitometry, were used in the clearance, autopsy, and liver perfusion experiments described below.
Trypsin was purchased from Worthington Biochemicals, Freehold, NJ. This preparation was 70% active as determined by active site titration (24) . Bovine serum albumin was obtained from Sigma and macroalbumin was prepared as described (25) . Pancreatic trypsin inhibitor (PTI) was purchased under the trade name Trasylol from Mobay Chemical Co., Pittsburgh, PA. Human a2M was purified as previously described (15 Organ distribution studies. Animals were injected with radiolabeled ligands and then sacrificed by cervical dislocation. The major body organs including the kidneys, liver, lungs, heart, spleen, stomach, and intestines were recovered. These organs were soaked in perfusion buffer, dried, and measured in a gamma counter for retained radioactivity. These studies were performed in triplicate, and the results were averaged.
RESULTS
Clearance of purified streptokinase and plasmin. The clearance of radiolabeled uncomplexed streptokinase deviated only slightly from apparent first order kinetics (Fig. 1) (17) (18) (19) 32) . Thrombin has been shown to bind to high affinity sites on cells without first complexing to protease inhibitors (33) ; this possibility was explored for plasmin. When injected into the circulation of mice, human plasminogen is cleared very slowly (Fig. 2) . The clearances of plasmin preparations activated with either streptokinase or urokinase are comparable and more rapid than plasminogen (50% elimination in 16 and 18 min, respectively). After reaction for 5 min with the active site alkylating agent PNPGB, plasmin, which can no longer react with protease inhibitors, is eliminated from the circulation at a rate approximating that of plasminogen. This is in sharp contrast to the results of the thrombin study in which both the active and inactive proteases behaved similarly (33) . It a2PI is the primary inhibitor of circulating plasmin; however, under certain conditions a2M may complex plasmin as well (32) . The complex formed between a2PI and plasmin is extremely stable at neutral pH (34) . Reactions between a2M and proteases are irreversible (35) . In the following studies plasmin complexes were formed in vitro with these two protease inhibitors and injected either alone or in the presence of competing ligand.
When incubated with an equimolar concentration of a2PI, radiolabeled plasmin was >99% inactivated as measured by its ability to hydrolyze the substrate S-2251. The clearance of 6 pmol of a2PI-_251-plasmin complex occurred at only a slightly decreased rate compared with free plasmin (Fig. 3 ). Approximately 20 min were required for 50% of the radioligand to be removed from the circulation. The same radiolabeled preparation was then injected in the presence of a large molar excess of unlabeled a2PI-plasmin complex. Greater than 50% of the injected radioligand consistently remained in the circulation at 75 min suggesting that clearance of a2PI-plasmin involves a specific and saturable pathway. A second competition experiment was performed in which a2M-trypsin complex was the cold competing ligand present in a large molar excess. a2M-protease complexes are removed from the circulation by a well studied receptor in the reticuloendothelial system (15, 36, 37) . A 700-fold molar excess of a2M-trypsin failed to retard the clearance of a2PI-plasmin complex indicating that a2PI-plasmin is eliminated from the circulation by a pathway distinct from that which recognizes a2M-protease.
Unlike a2PI, a2M reacts and becomes saturated with plasmin in a progressive, relatively slow reaction (38 Catabolism of Plasminogen Activator Complex jected in the presence of a 1,000-fold molar excess of unlabeled a2M-trypsin. This result indicates that a2M-plasmin binds to the same receptor system that recognizes a2M-trypsin and a2M-methylamine, but not unreacted a2M (15, 36, 37, 39) . a2M-plasmin complex with radiolabeled a2M cleared equivalently to a2M-plasmin with radiolabeled plasmin, suggesting that the complex clears as a unit. In either case, the clearance of a2M-plasmin was marginally slower than a2M-trypsin. A possible explanation for this is discussed below.
In a final set of plasmin clearance studies, uncomplexed '251-plasmin was injected in the presence of large molar excesses of unlabeled a2PI-plasmin or a2M-trypsin. The competing ligands were prepared so that the protease inhibitor present was saturated with protease and no longer reactive. The competing and radiolabeled ligands were injected sequentially with separate syringes to avoid reversible association of free radiolabeled ligand with competing complex, as has been described (40) . Considerable competition for clearance was demonstrable when the competing ligand was a2PI-plasmin (Fig. 5) . a2M-trypsin, however, failed to retard the clearance of the radiolabeled plasmin. These studies strongly suggest that the major fraction of the injected plasmin is binding to and clearing as a mouse a2PI complex.
Clearance of streptokinase activator complex. Radiolabeled streptokinase (30 pmol) was incubated with an equimolar concentration of plasminogen for 5, 20, and 30 min. Streptokinase-plasminogen complex is converted intramolecularly into streptokinase-plasmin during this time period (41) . All three preparations FIGURE 5 The role of a2PI and a2M in the neutralization and clearance of circulating plasmin. 125I-streptokinase. The clearance of this preparation was indistinguishable from that of activator complex formed with plasminogen. Activator complex formed from '25I-plasminogen and unlabeled streptokinase cleared equivalently to complex formed with radiolabeled streptokinase. These data suggest that the complex clears as an intact unit. Alternatively, the possibility that the two proteins clear through separate accelerated pathways is also consistent with these data. Plasminogen activator complexes were prepared in which either streptokinase or plasminogen was radiolabeled. These complexes were then incubated with PNPGB for 10 min. The inactivated complexes cleared at a much slower rate than active complex (Fig. 6) . Reaction of '25I-streptokinase-plasmin with excess PTI for 40 FIGURE 6 The clearance of plasminogen activator complexes formed from purified streptokinase and plasminogen. Activator complexes formed with 1251-streptokinase (0) and with 1251-plasminogen (0) were studied without modification. Streptokinase-'25I-plasmin was inactivated with excess PNPGB as described in the text (0). The equivalent inactivation was performed with complex containing radiolabeled streptokinase (0). 125I Streptokinase-plasmin was reacted with excess PTI for 40 min before injection (@). which protein was radiolabeled. A possible explanation for this observation is discussed below. The clearance of inactivated complex in all of the above experiments was, nevertheless, slower than the clearances of either streptokinase or plasmin alone. Therefore, activity is critical for the retention of the greatly accelerated clearance rate demonstrated by plasminogen activator complex.
Clearance of proteins incubated with plasma. Radiolabeled streptokinase (0.2 nmol) was incubated with 450 pi of mouse plasma for 30 min at 23 and 37°C. Plasminogen-depleted plasma was then substituted for untreated plasma and the same studies repeated. The clearances of these preparations were equivalent to each other and to the clearance of unreacted streptokinase shown in Fig. 1 . These data support the previous finding that streptokinase does not form activator complex with plasminogen from the mouse (11) . In addition, it is considered unlikely that any type of streptokinase-plasma protein interaction represents the rate limiting step in the clearance of the uncomplexed radioligand.
Human plasma was substituted for mouse plasma and the incubations described above were performed for 7 min. This substitution accelerated the clearance of the '251-streptokinase so that it was equivalent to that demonstrated by activator complex formed with purified plasminogen, suggesting that complex formation occurs readily in human plasma. Incubation of '251-streptokinase with human plasminogen-depleted plasma resulted in clearances that were somewhat variable; however, always intermediate between the clearances of activator complex and uncomplexed streptokinase. It is possible that this variability reflects strong association between streptokinase and even extremely small quantities of retained plasminogen in the modified plasma preparations.
Organ distribution studies. Radiolabeled streptokinase, plasmin, and activator complex were injected intravenously. Table I shows the organ distribution of radioactivity at the given times. Streptokinase initially concentrates in the liver. At later time points, there is an apparent transfer of radioactivity to the gut. This transfer has been observed before (9, 10) . Comparable results were obtained when activator complex and plasmin were studied. Again, radioactivity was initially sequestered in the liver. At later time points radioligand accumulated in the gut especially with activator complex containing 1251-streptokinase. The possibility that the biliary system is involved in this process has been suggested for uncomplexed streptokinase (10). Immunoglobulin A-secretory component is transported rapidly and intact from the liver to the small intestine via the biliary system (42) . The studies described here do not provide information concerning the nature of the radioactivity transported once the radiolabeled protein is bound in the liver.
Liver perfusion experiments. Radiolabeled plasmin (20 pmol) was inactivated with PNPGB, incubated for 10 min at 37°C in perfusion buffer, and injected into a prepared liver. The perfused and thoroughly washed liver retained 2.2% of the administered radioligand. An equivalent quantity of 1251-plasmin was perfused into a liver without prior inactivation with PNPGB. Only 2.3% of the administered radioligand was retained. Incubating the plasmin for 10 min at 37°C with whole blood freshly drawn from a mouse instead of perfusion buffer increased radioactivity retention in the liver to 12.1%. In experiments described above, alkylated plasmin cleared at a slow rate com- Activator complex containing radiolabeled plasmin was incubated for 10 min at 23 and 37°C in perfusion buffer. Perfused livers retained 1.8 and 2.2% of these radioligands, respectively. Incubation for 10 min at 37°C in whole blood increased the hepatic binding of the radioligand to 8.0%. These results were confirmed for activator complex containing 1251-streptokinase and unlabeled plasmin (10.2% hepatic retention of radioligand following incubation in whole blood as opposed to 2.6% following incubation in perfusion buffer). Substitution of mouse plasma for whole blood had no significant effect on the hepatic binding of either moiety in activator complex (8.3% retention of plasmin and 9.8% of retention of streptokinase). These data suggest that activator complex, like plasmin, interacts with plasma proteins mediating hepatic binding.
Role of protease inhibitors in activator complex clearance. Plasma elimination studies have been used to demonstrate that activity is critical for the catabolism of activator complex. Liver perfusion experiments yielded results suggesting that plasma proteins were involved in the pathway. The roles of the plasma protease inhibitors a2M and a2PI were, therefore, investigated. Clearance experiments were performed in the presence of competing ligands using the same technique applied to study uncomplexed plasmin clearance (Fig.5 ) . The clearance of activator complex (16 pmol) formed with radiolabeled plasminogen was significantly slower when unlabeled a2M-trypsin complex was injected first (Fig. 7) . The level of competition observed was dependent upon the molar excess of competing ligand used; however, a 220-fold molar excess of a2M-trypsin decreased radioligand clearance well outside the limits of experimental error. An equivalent aliquot of plasminogen activator was cleared in the presence of a 550-fold molar excess of unlabeled a2PI-plasmin. Competition was not detectable. a2M and a2PI complexes have been shown to clear through separate noncompetitive pathways. The catabolism of plasmin and activator complex, therefore, depend on reactions with different proteases inhibitors; a2PI and a2M, respectively.
To further characterize the reaction of plasminogen activator complex with a2M, competition experiments were performed with unlabeled a2M-trypsin and activator complex containing radiolabeled streptokinase. Time (min) FIGURE 7 Clearance competition between activator complex containing '251-plasmin and the unlabeled ligands a2M-trypsin and a2PI-plasmin. 16 pmol of activator complex were injected alone (0), in the presence of a 220-fold molar excess of a2M-trypsin (a), in the presence of a 550-fold molar excess of a2M-trypsin (V), and in the presence of a 550-fold molar excess of a2PI-plasmin (A). dination with lactoperoxidase than was plasminogen. The maximum molar ratio of a2M-trypsin to activator complex studied was, therefore, somewhat lower than that used in the experiments in which the plasminogen was radiolabeled. No competition was observed, however, when 200 pmol of complex were injected in the presence of a 250-fold molar excess of a2M-trypsin. These experiments suggest that the clearances of streptokinase and plasmin, when injected as a complex, involve separate pathways even though both are eliminated in the liver at accelerated rates compared with the individual proteins. One possible explanation for these data is that activator complex is relatively easily dissociated at 37°C. This model is, however, inconsistent with experiments that show prolonged clearance of '251-streptokinase in complex inactivated with PTI.
In addition, the rapid clearance of the plasmin moiety in activator complex as compared with uncomplexed plasmin (Fig. 2) is inconsistent with a model of simple dissociation. A second explanation consistent with the data is that plasmin is transferred from activator complex to a2M under conditions where dissociation of the isolated complex does not occur.
Liver perfusion experiments were used to assess the importance of a2M in the catabolism of the streptokinase moiety in activator complex. Plasminogen activator (0.2 nmol) formed with '251-streptokinase was incubated at 37°C for 10 min with 450 Ml of perfusion buffer containing 1.7 mg/ml of human a2M. Hepatic retention of the radiolabel was 7.5%, compared to 2.6% measured when the same incubation was performed in the absence of a2M. Only 2.5% of the perfused radiolabel was retained after incubation of the activator complex with a2M at 230C. Significant hepatic binding of the streptokinase in activator complex was mediated by an interaction with a2M at 37°C, even though the clearance experiments described above suggest that streptokinase is not transferred to a2M under similar conditions. The reaction or series of reactions responsible for the liver perfusion results was obtained with human protease inhibitor at 37°C and not duplicated at 23°C. In a previous study, a2M was shown not to interact with streptokinase activator complex (13) . The results of this study were, however, obtained at 40C, and are therefore not inconsistent with those presented here.
Polyacrylamide gel electrophoresis. Streptokinase, plasmin, and streptokinase activator complex were reacted with a2M for 40 min at 23 and 370C using both radiolabeled and nonradiolabeled proteins. Gels containing radiolabeled protein were sectioned as described in Methods. Protein content in electrophoretic bands was determined from measurement of the radioactivity contained within the gel sections with a gamma counter. Control experiments demonstrated no overlap between a2M bands and the positions of the unreacted radiolabeled proteins studied. The electrophoresis patterns resulting from all of the reactions described below were equivalent when nonradiolabeled proteins were substituted for radiolabeled proteins.
After reaction with proteases a2M undergoes a conformational change that results in an increase in the electrophoretic mobility of the complexed inhibitor relative to the unreacted protein (43) . This increased mobility is clearly demonstrated following reaction with trypsin (Fig. 8) . Reaction is apparently complete at 23 and 370C. The electrophoretic mobility of a2M after reaction with plasmin is also increased. The diffuse band obtained may reflect the size of plasmin relative to trypsin and potential heterogeneity in the orientation of plasmin in complex with the inhibitor. The migration of this a2M complex is indistinguishable following reactions at 23 and 370C. The number of moles of radiolabeled plasmin incorporated into complex is essentially equivalent at the two temperatures (1.2 mol plasmin/mol of a2M at 230C and 1.1 mol plasmin/mol a2M at 370C).
a2M was incubated at 23 and 370C with a fivefold molar excess of streptokinase for 40 inhibitor electrophoretic band (Table II) . These findings are in agreement with a previous study performed at ambient temperature (13) . Activator complex was prepared in the presence of a twofold molar excess of streptokinase. Incubation of a2M with a fourfold molar excess of activator complex resulted in a temperature dependent reaction similar to that detected in the liver perfusion studies. The electrophoretic migration of the a2M was significantly altered after incubation at 370C. At 230C the mobility was, at best, marginally altered compared with unreacted a2M. This result was confirmed for activator complex formed with radiolabeled streptokinase and complex formed with radiolabeled plasminogen. Only the radiolabeled plasmin became significantly associated with the a2M (Table II) . If streptokinase participated in the formation of a ternary complex, the association was too weak to be maintained during the course of the electrophoresis experiments. The association of 0.8 mol of '251-plasmin with 1.0 mol of a2M after incubation at 370C represented a fourfold increase over the association measured at 23°C. These data are in good agreement with the in vivo studies, which suggest that activator complex reacts with a2M resulting in the transfer of plasmin to the protease inhibitor.
Complex formation between a2M and protease is initiated by proteolytic attack resulting in the cleavage of the a2M subunit (180,000 mol wt) into two polypeptide chains that are nearly equivalent in size (44) . NaDODSO4 gel electrophoresis of samples reduced DISCUSSION The first aim of this investigation was to study the plasma elimination of uncomplexed streptokinase. Previous studies have included organ distribution experiments in mice and clearance studies in dogs (8) (9) (10) . These two species have plasminogens with different affinities for streptokinase (11, 47) . It is conceivable, therefore, that different ligands were actually studied by the two experimental techniques. In the present study radiolabeled streptokinase was sequestered in the liver following intravenous injection into mice. Clearance in mice was more rapid than in dogs (8) (9) (10) despite the inability of the radioligand to form activator complex in the rodent circulation. Plasma elimination of streptokinase was dominated by one major phase and no evidence was obtained implicating plasma protein interaction in the clearance pathway.
The organ primarily responsible for the clearance of plasmin was the liver. Maintenance of an uninhibited active site was critical for the clearance of this ligand. Hepatic binding of '251-plasmin occurred only after the protease was incubated with blood. These experiments suggest that reaction with protease inhibitors is the only significant mechanism mediating the plasma elimination of plasmin. a2PI-plasmin, prepared in vitro, cleared from the circulation of mice, although at a somewhat slower rate than some of the other protease inhibitor complexes (14, 15) . Large molar excesses of unlabeled a2PI-plasmin significantly retarded the clearance of the radiolabeled complex. Competition indicates that the pathway for catabolism of a2PI-plasmin is specific and saturable. Clearance of a2PI-plasmin did not involve the a2M receptor system. This information permitted the use of clearance competition experiments to demonstrate that plasmin is bound primarily to a2PI and not to a2M when injected into the circulation.
a2M-plasmin was cleared by the same receptor system that binds a2M-trypsin and a2M-methylamine (15) . This receptor recognizes conformational change in the a2M macromolecule and is grossly uninfluenced by the bound ligand. The slightly prolonged clearance rate of a2M-plasmin relative to a2M-trypsin and a2M-methylamine may reflect some minor steric hindrance to receptor binding caused by the relatively large plasmin molecule. The strong affinity of streptokinase for human plasminogen was a major consideration in the decision to study reactions that might take place in the circulation that lead to the neutralization of the activator complex. The clearance of streptokinase following incubation with human plasma was equivalent to the clearance of activator complex formed with purified plasminogen. It is therefore likely that the fraction of free streptokinase circulating in human plasma after intravenous infusion is low.
Plasminogen activator complex cleared from the circulation extremely quickly compared with uncomplexed plasmin and streptokinase. First order clearance kinetics were not demonstrated by activator complex, suggesting some heterogeneity in the elimination pathway. Nevertheless, the percentage of rapidly clearing radioligand consistently represented the majority of the injected preparation.
The clearance of activator complex was studied in the presence of large molar excesses of unlabeled a2PI-plasmin and a2M-trypsin. The competing ligands were saturated complexes and they did not contribute to the protease inhibitory capacity of the plasma. a2M-trypsin significantly retarded the clearance of the plasmin in activator complex, whereas a2PI-plasmin did not, in contrast to the result observed for uncomplexed plasmin. No competition was detected when radiolabeled streptokinase was incorporated into activator complex and studied in the presence of competing a2M-trypsin. These data are consistent with a model in which plasmin is transferred from streptokinase to a2M. Competing a2M-trypsin would not be expected to have an effect on the reaction of activator complex with circulating mouse a2M. Once reaction has occurred, competing ligand would prolong the clearance of the plasmin that is bound to a2M, but have no effect on the streptokinase that is not associated with the protease inhibitor.
Two mechanisms are recognized whereby plasmin may be transferred from activator complex to a2M. Transfer may result from the establishment of equilibrium between independent reactions (the dissociation of activator complex and reaction between a2M and plasmin). Alternatively, transfer may involve activator complex attack on an a2M "bait region," resulting in the trapping of the plasmin by the protease inhibitor and dissociation of the streptokinase. Although these two mechanisms are not mutually exclusive, the second is thought to predominate in vivo for the following reasons. (a) The independent reactions mechanism fails to explain the accelerated clearance of '251-plasmin in activator complex. (b) The clearance rate of the streptokinase in activator complex is decreased by inhibition of the active site on the plasmin moiety with either PNPGB or PTI. It is unlikely that this result reflects a change in the association properties of the complex since PTI does not alter the affinity of streptokinase for plasmin (4), even though PNPGB may (48) . Circulating inactive plasmin would not be expected to prolong the clearance rate of streptokinase since excess human plasminogen did not have this effect when it was injected along with the activator complex formed in vitro with human plasma. There is therefore, no apparent explanation for the clearance of 1251-streptokinase in PTI inactivated complex that is consistent with independent dissociation. (c) It is difficult to explain the predominant role of a2M in the binding of plasmin with the first model of independent reactions. Streptokinase activator complex and uncomplexed plasmin are known to have different substrate specificities (41) . Activator complex is less reactive with a2PI than is free plasmin (3). The reaction of circulating plasmin and streptokinase activator complex with different protease inhibitors is most simply explained as different enzymes attacking preferred substrates. It is concluded that the mechanism of plasmin transfer most consistent with all of the data accumulated in this investigation is the second, which implicates a2M as playing an active role in the dissociation of the activator complex. When the active site of the activator complex is inhibited, the clearance of the streptokinase in the complex become dependent on passive dissociation, a significantly slower reaction (Fig. 6) . Passively dissociated streptokinase still may be cleared in the liver while alkylated plasmin is not, explaining the discrepancy in the clearance rates of the two moieties in PNPGB-treated plasmin.
These studies raise two additional questions, both of which are speculative at present. The first involves Catabolism of Plasminogen Activator Complex how a2M-'251-plasmin formed in vivo from reaction with activator complex clears more rapidly than a2M-plasmin prepared in vitro and administered directly. If one accepts the "plasmin transfer" model, it may be postulated that transfer results in an orientation of the plasmin in complex with a2M, which is different from that found after the binding of free plasmin by a2M. Macrophage binding studies are presently underway to test this hypothesis. Finally, why does streptokinase demonstrate accelerated clearance following dissociation from activator complex? Fragmentation of streptokinase is known to occur rapidly when in complex with plasmin(ogen), although no fragments are lost (49) . In this investigation, a hepatic clearance pathway for streptokinase that appeared not to involve plasminogen was detected. Further studies will be required to determine whether dissociated streptokinase utilizes the same pathway.
